Zimmer Biomet Holdings Inc. (NYSE:ZBH) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $126.65 and last traded at $126.25, with a volume of 301,606 shares traded. The stock had previously closed at $125.57.

ZBH has been the subject of a number of research analyst reports. Piper Jaffray Cos. restated an “overweight” rating and set a $125.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, June 21st. Royal Bank Of Canada boosted their price objective on Zimmer Biomet Holdings from $120.00 to $132.00 and gave the stock an “outperform” rating in a report on Friday, April 15th. Barclays PLC boosted their price objective on Zimmer Biomet Holdings from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, April 29th. Goldman Sachs Group Inc. reduced their price objective on Zimmer Biomet Holdings from $113.00 to $111.00 in a report on Friday, April 8th. Finally, Jefferies Group restated a “buy” rating and set a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Wednesday, June 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $124.50.

The firm’s 50 day moving average price is $120.53 and its 200-day moving average price is $109.30. The company has a market capitalization of $24.99 billion and a price-to-earnings ratio of 308.92.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.93 by $0.07. During the same period last year, the business posted $1.54 earnings per share. The business earned $1.90 billion during the quarter, compared to the consensus estimate of $1.88 billion. The firm’s quarterly revenue was up 67.8% on a year-over-year basis. Analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.96 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, June 24th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.77%. The ex-dividend date is Wednesday, June 22nd.

In other Zimmer Biomet Holdings news, CAO Tony W. Collins sold 3,611 shares of the firm’s stock in a transaction on Tuesday, June 14th. The shares were sold at an average price of $116.43, for a total value of $420,428.73. Following the completion of the transaction, the chief accounting officer now directly owns 3,245 shares of the company’s stock, valued at approximately $377,815.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Stuart G. Kleopfer sold 11,000 shares of the firm’s stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $119.45, for a total transaction of $1,313,950.00. Following the completion of the transaction, the insider now directly owns 7,609 shares of the company’s stock, valued at $908,895.05. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Whittier Trust Co. purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $1,022,000. Employees Retirement System of Texas purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $1,026,000. Liberty Mutual Group Asset Management Inc. purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $1,029,000. Amica Mutual Insurance Co. purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $1,064,000. Finally, Commerzbank Aktiengesellschaft FI purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $1,104,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.